WO2023113586A1 - Formulation à base lipidique à usage topique ophtalmique contenant un extrait de myrtille arbustive - Google Patents

Formulation à base lipidique à usage topique ophtalmique contenant un extrait de myrtille arbustive Download PDF

Info

Publication number
WO2023113586A1
WO2023113586A1 PCT/MX2022/050120 MX2022050120W WO2023113586A1 WO 2023113586 A1 WO2023113586 A1 WO 2023113586A1 MX 2022050120 W MX2022050120 W MX 2022050120W WO 2023113586 A1 WO2023113586 A1 WO 2023113586A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
component
formulation
eyeball
tissues
Prior art date
Application number
PCT/MX2022/050120
Other languages
English (en)
Spanish (es)
Inventor
Arturo SANTOS GARCÍA
Juan Carlos ALTAMIRANO VALLEJO
José NAVARRO PARTIDA
Original Assignee
Centro De Retina Médica Y Quirúrgica, S.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Retina Médica Y Quirúrgica, S.C. filed Critical Centro De Retina Médica Y Quirúrgica, S.C.
Publication of WO2023113586A1 publication Critical patent/WO2023113586A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention is related to the field of biotechnology and medicine.
  • the invention consists of a lipid-based formulation for topical ophthalmic use that functions as a liposomal delivery system for the bioactive agents contained in the blueberry extract in white tissues of the posterior segment of the eyeball in humans.
  • the invention is useful for maintaining health and reducing the risk of developing chronic-degenerative processes in the infraocular tissues, including those of the posterior segment of the eyeball due to its anti-inflammatory, anti-angiogenic, anti-fibrotic and antioxidant activity.
  • the posterior segment of the eye is the part of the eyeball that includes the retina and its blood vessels, as well as the head of the optic nerve. It is in this tissue, and in particular in its central area called the macula, where the vision generation process takes place.
  • Said structure is a complex tissue formed by multiple layers of neurons, which can be functionally divided into two parts: one external and one internal.
  • the external part comprises the Retinal Pigment Epithelium (RPE) and its basal lamina called Bruch's membrane, where both maintain the integrity of the retina. outer blood-retinal barrier.
  • RPE Retinal Pigment Epithelium
  • Bruch's membrane basal lamina
  • the internal part comprises the photosensitive layer of cones and rods and their nerve connections that capture light and convert it into electrical nerve impulses, which are transmitted through the optic nerve, having in these tissues the vascular structure that forms the internal blood-retinal barrier.
  • These barriers are part of the anatomical and physiological barriers of the eyeball, which limit the penetration and bioavailability of bioactives in the retina when they are administered topically or systemically.
  • anthocyanins AC
  • resveratrol RV
  • pteroestil bene PS
  • anthocyanins AC
  • resveratrol RV
  • pteroestil bene PS
  • Both anthocyanins, resveratrol, and pteroestil bene have been found to have a potent anti-inflammatory effect by significantly reducing the expression of anti-inflammatory mediators, tumor necrosis factor alpha (TNF-a), interleukins (IL-10, I L-6, MMP-2), metalloproteinases (MMP-9).
  • TNF-a tumor necrosis factor alpha
  • IL-10 interleukins
  • I L-6 I L-6
  • MMP-2 metalloproteinases
  • anthocyanins and pteroestil beno restore homeostasis between oxygenases and oxidative enzymes by decreasing the expression of cyclooxygenase 2 (COX-2) and restoring the antioxidant activity of enzymes such as superoxide dismutase 1 (SOD1). and peroxiredoxin 4 (PRDX4).
  • Anthocyanins, resveratrol, and pterostilbene are not only found in blueberry extract, as there are other natural sources.
  • anthocyanins can be found in high amounts in blueberry extract (Vaccinium Macrocarpon and Vaccinium Oxycoccos) and raspberry (Rubus Ideaeus) extract.
  • Resveratrol is present not only in blueberry extract (Vaccinium Myrtillys and Vaccinium Corymbosum), but also in other extracts such as grape (Vitris Viniforme) and raspberry (Rubus Ideaeus) extract.
  • Pterostilbene can be found in large amounts in blueberry extract (Vaccinium Myrtillys and Vaccinium Corymbosum), almond (Prunus Dulc ⁇ s) and raspberry (Rubus Ideaeus) extract.
  • Vitamin C also known as ascorbic acid by its chemical formulation, is a compound commonly found in fresh fruits, as well as vegetables. This acid compound is subjected to oxidation becoming dehydroascorbic acid, which is why it participates as a cofactor of multiple hydroxylation reactions, thus involved in the biosynthesis of collagen, which is the main structural protein of connective tissue. That is the main reason, not the only one, why it is associated with the prevention of capillary fragility, its requirements are 50 mg per day. Vitamin E is a fat-soluble vitamin that has antioxidant effects and works uniquely by breaking the lipid peroxidation chain reaction. This action is crucial to stabilize cell membranes and has been shown to prevent changes to the ocular surface and retina.
  • Vitamin E can regenerate other antioxidants such as ascorbic acid or glutathione.
  • a high concentration of vitamin E similar to that found in the AREDS (Age-Related Eye Disease Studies) formula may decrease the risk of progression of age-related macular degeneration.
  • Vitamin E exists naturally as eight different fat-soluble compounds of tocopherols and tocotrienols. Sunflower seeds and walnuts, as well as almonds, spinach and those dark leafy vegetables are rich sources of vitamin E. Vitamin D has shown important effects as an antioxidant in retinal vasculopathies such as diabetic retinopathy.
  • Magnesium is an essential cation as a cofactor in phosphate-using enzymatic metabolic pathways. Hypomagnesemia, related to increased losses or decreased income, is closely related to the metabolic syndrome observed during diabetes or its complications; in fact, it is considered to be the most common electrolyte disturbance in diabetic subjects. Since magnesium is predominantly an intracellular ion, the plasma concentration may not reflect the status of magnesium content. of the organism. Magnesium deficiencies can cause alterations in the activity of the enzyme tyrosine kinase and in the number of insulin receptors and an increase in the concentration of intracellular calcium, all of which is related to resistance to the action of insulin.
  • Zinc has the potential to have positive effects on retinal cells, so its absence is related to dark adaptation defects.
  • carotenoids such as lutein and zeaxanthin, which are yellow pigments found in vegetables and other plants. Both have the potential to absorb excess light to prevent damage to the neurosensory retina, especially short-wavelength light rays such as violet and blue. Its use is widely used and recognized in ophthalmology as preventive and/or conservative of retinal health in patients with age-related macular degeneration. Regardless of their origin, these compounds of vegetable and mineral origin could be administered for use in ophthalmology, seeking adequate concentrations for the preservation of the health of the various structures of the eye and/or in some pathologies.
  • Topical instillation is the non-invasive route preferred by ophthalmology specialists worldwide for the administration of drugs and molecules for the treatment of diseases of the anterior segment of the eyeball. This route is non-invasive, with few adverse effects, lower costs and better patient adherence, since it does not require complex facilities or highly specialized human capital for its administration.
  • the dynamic barriers of the eye facilitate the elimination of the poor concentrations that manage to reach the interior of the eyeball.
  • metabolic barriers cytochrome P450 and lysosomal enzymes
  • intravitreal injection is the delivery method most used by specialists in ophthalmology and retina to be able to deliver adequate and clinically effective concentrations for the treatment of diseases that affect the posterior segment of the eyeball.
  • its use is related to serious ocular adverse events such as endophthalmitis, retinal detachment, cataracts, and vitreous hemorrhage, among others.
  • this treatment modality is expensive, painful, with little access to the general population (requiring hospital facilities and highly trained human capital for its administration), and generates little attachment and great discomfort both to the user (patients) and to the medical team.
  • systemic administration oral route
  • herbal extracts including blueberry extract
  • blindness is currently one of the most relevant disabilities in the world, since the human being is primarily a visual entity, so its development, in addition to being an individual catastrophe, represents a family, social and economic burden. relevant.
  • Conditions such as diabetic retinopathy have a high cost in their treatment.
  • the annual expense per eye for the treatment of diabetic macular edema ranges from USD 14,000 to USD 25,000 and in Mexico from USD 66,00 to USD 114,000.
  • Age-Related Macular Degeneration currently represents a US$16 billion market.
  • the negative experience, and the discomfort generated by the repeated application of drug injections, added to the essential use of facilities and specialized human capital result in poor adherence and access to treatment, as well as saturation in health services, being It is essential to seek treatment alternatives and above all prevention.
  • the eyeball presents significantly greater challenges than other organs for the delivery of medicines, molecules and herbal extracts, given the large number of anatomical and physiological barriers that it presents, so the greatest challenge for the release of drugs, molecules and extracts herbalists is to find a delivery method that is highly effective, with a high safety profile, increases patient adherence, and has mass access to it.
  • Diabetic Retinopathy is a problem in Latin American countries and in Mexico given that it disables economically active individuals, resulting in an impact on the economy of health systems and countries. This makes the field of ophthalmic therapeutics particularly interesting for scientific-technological researchers and entrepreneurs.
  • Anatomical barriers include structures such as the corneal epithelium, conjunctiva, sclera, and the two blood-retinal barriers; and physiological barriers include processes such as the tear film, its drainage systems, and blinking, as well as the aqueous humor production, flow, and absorption system, and the composition of the vitreous gel. Said barriers limit the systemic penetration that one or several bioactives present in a herbal extract could have.
  • the ideal route of administration is topical, since it is easy for the patient to use, with few adverse effects and with adequate control of the frequency used.
  • bioavailability of bioactives from herbal extracts after topical ophthalmic administration of conventional formulations, is inefficient for target tissues of the posterior segment of the eyeball, since penetration is usually less than 5%, which constitutes a very limited limitation. important and with obtaining poor bioavailability of these.
  • those conditions that affect the health of the target tissues in the posterior segment of the eyeball, such as the retina are not candidates for this route of administration.
  • Extracts such as blueberry that have an additive effect of bioactives AC, RV, and PS can be administered topically, with adequate penetration efficiency and bioavailability by using a lipid-based formulation.
  • the cranberry lutein softgel consists of a capsule shell and a content, in which the content is stores in capsule shell; the content is composed of the following components in parts by weight: 43 to 47 parts of cranberry extract, 20 to 23 parts of zinc gluconate, 14 to 16 parts of vitamin C, 1 1 to 14 parts of powdered lutein, 3 to 4 parts vitamin E, 0.2 to 1 part vitamin A, 143 to 146 parts soybean oil, and 6 to 9 parts beeswax; and the capsule shell is composed of the following components in parts by weight: 190 to 210 parts of gelatin, 70 to 90 parts of glycerin, 190 to 210 parts of purified water, and 9 to 10 parts of caramel color.
  • the capsule is used to improve eyesight.
  • This invention is different in content and application from the developed formulation.
  • the invention CN104606565A dated February 15, 2015, describes a traditional Chinese medicine and in particular refers to capsules for preventing and treating ophthalmic diseases.
  • the capsule contents comprise 40-45 parts of a traditional Chinese medicine extract, 5-7 parts of semen boitae, 8-12 parts of orris, 4-5 parts of allium victorialis, 20 parts of peony seed oil and 5-10 parts of blueberries.
  • anthocyanin contained in blueberries is an important element to maintain eye health and prevent visual impairment; and peony seed oil has the effect of improving autoimmunity, lowering blood fat and blood pressure, preventing diabetes, preventing and treating cancers, cleaning up dangerous substances in the blood, preventing and treating heart disease, refreshing and improving intelligence, improve attention span and memory and beautification.
  • the medications are compatible and have the effect of treating both the symptoms and the root causes of eyestrain.
  • TCM capsules have rapid pharmacological effects and good curative effects and have no side effects or toxic effects, and the effective rate is 100 percent. Based on the foregoing, this invention is different from the developed formulation both in content and application.
  • the invention WO2015177353A1 dated May 22, 2014, describes a composition that contains, as active principle, ectoin, hydroxyectoin and/or salts, esters or amides of these compounds, for the treatment and/or prophylaxis of eye diseases associated with an alteration of the tear film.
  • this can be keratoconjunctivitis sicca.
  • these compounds can prevent the breakdown of the outer lipid layer of the tear film and thus prevent undesired rapid evaporation of tear fluid. Based on the foregoing, this invention is different from the developed formulation both in content and application.
  • the invention CN 103860625A describes a cranberry extract ophthalmic preparation and a preparation method and uses thereof and belongs to the technical field of ocular ophthalmic preparations.
  • the technical problem to be solved is to provide a blueberry extract ophthalmic preparation.
  • the cranberry extract ophthalmic preparation comprises a cranberry extract active ingredient.
  • the eye ophthalmic preparation can effectively treat, prevent or alleviate cataracts, glaucoma, vitreous opacity, macular degeneration, retinopathy, optic atrophy, keratitis, wind-induced epiphora, presbyopia, myopia, eyestrain, blurred vision, conjunctival burn, conjunctivitis, corneal ulcer , eyelid eczema, floaters or trachoma and other eye diseases.
  • a new preparation is provided for the treatment of cataracts, glaucoma, vitreous opacity, macular degeneration, retinopathy, optic atrophy, keratitis, wind-induced epiphora, presbyopia, myopia, visual fatigue, vision blur, conjunctival burn, conjunctivitis, corneal ulcer, eyelid eczema, floaters or trachoma and other eye diseases, and meet the strong demand to protect eyes.
  • this invention is different from the formulation developed both in content and application, this based on the capacity of the formulation object of this invention.
  • the invention LT2017521 A dated July 28, 2017, describes eye drops, which contain extracts of carrot and blueberry, with application for the conservation of visual acuity, and the production method thereof.
  • the ophthalmic pharmaceutical formulation contains extracts of carrot and blueberry used with any basic mono or multicomponent solution of neutral acidity, where the extracts of carrot and blueberry in the solution do not exceed 10% by weight of the solution, the proportion of extracts of carrot and cranberry in the solution is from 3: 7 to 7: 3, and the pH of the resulting preparation is in the range from 6.9 to 7.6. Based on the foregoing, this invention is different from the formulation developed both in content and application.
  • the invention MX2017016991 A, dated December 20, 2017, describes a nutraceutical formulation of cranberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption.
  • the invention belongs to the field of ophthalmology and has been developed as an adjuvant to preserve the health of the precorneal film and the ocular surface.
  • This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, it improves tear quality, since these compounds have antimicrobial and anti-inflammatory properties.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • omega-3 obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, it improves tear quality, since these compounds have antimicrobial and anti-inflammatory properties.
  • the formulation has been designed as an adjuvant to preserve the health of the precorneal film.
  • the object of this invention is to make available a lipid-based formulation for topical ophthalmic use that functions as a liposomal delivery system for the bioactive agents contained in the blueberry extract (EA) in tissues. white of the posterior segment of the eyeball in humans.
  • the formulation comprises a combination of polyphenol-rich blueberry extract as active ingredient, polyethylene glycol glyceryl dimyristate (PEG-12) as structural component of liposomes, ethyl alcohol as organic solvent for liposome generation, Kolliphor® HS 15 as penetration enhancer, anhydrous citric acid and dehydrated sodium citrate as buffers and grade 2 purified water as inorganic solvent.
  • the formulations of the present invention are useful to maintain health and reduce the risk of developing chronic-degenerative processes in the infraocular tissues, including those of the posterior segment of the eyeball due to their anti-inflammatory, anti-angiogenic, anti-inflammatory, and anti-inflammatory activity. fibrotic and antioxidant.
  • the invention comprises a topical ophthalmic formulation of lipid-based blueberry extract where the value lies in allowing more efficient penetration and bioavailability of its b ⁇ oactives in white tissues of the posterior segment of the eyeball in humans.
  • this lipid-based formulation represents an advantage for the topical use of these bioactives; so that the invention consists of a lipid-based formulation for topical ophthalmic use that functions as a liposomal delivery system for the bioactive agents contained in the blueberry extract in white tissues of the posterior segment of the eyeball in humans.
  • the invention is useful for maintaining health and reducing the risk of developing chronic-degenerative processes in the infraocular tissues, including those of the posterior segment of the eyeball due to its anti-inflammatory, anti-angiogenic, anti-fibrotic and antioxidant activity.
  • a lipid-based ophthalmic topical formulation has the potential to be a release method that makes the penetration of the barriers of the eyeball more efficient, thus achieving an increase in the bioavailability of bioactives in the white tissues of the posterior segment of the eyeball, such as the retina, minimizing the risks associated with other forms of administration local and/or systemic.
  • lipid-based formulation for ophthalmic topical use which contains blueberry extract as the main component to make more efficient the penetration and bioavailability of its bioactives in infraocular white tissues in humans, they are clearly shown in the following description.
  • compositions of the present invention contain an effective amount of blueberry extract.
  • concentration of the blueberry extract in the lipid-based formulations varies from 0.3 to 2 mg, that is to say, from 0.03 to 2% (p/v).
  • Blueberry extract has a large amount of polyphenol bioactive agents such as anthocyanins, resveratrol and bene pteroestil that have the potential to preserve health and reduce the risk of developing chronic-degenerative processes in intraocular tissues, including those of the posterior segment of the eyeball due to its anti-inflammatory, anti-angiogenic, anti-fibrotic and antioxidant activity.
  • Polyethylene glycol (PEG-12) glyceryl myristate is used as a structural component of liposomes at a concentration of 5-15% (w/v) and ethyl alcohol is used as an organic solvent for liposome generation at a concentration of 0.7 to 2.1% (v/v).
  • the formulation contains polyethylene glycol (15) -hydroxystearate or Kolliphor® HS15 from 2.5 to 7.5% (w/v), as a potent non-ionic solubilizer and emulsifying agent, with low toxicity proposed to act as a permeability enhancer.
  • Kolliphor® HS15 also promotes the transport of molecules across cell membranes by increasing the rate of endocytosis and stimulates the translocation of drugs through the pathway to cellular (affecting actin organization in the cell cytoskeleton with subsequent opening of tight junctions between cells).
  • aqueous compositions of the present invention optionally comprise further excipients selected from the group consisting of buffering agents, pH adjusting agents and preservatives.
  • buffering agents 0.04 to 0.16%
  • Sodium Citrate Dihydrate 0.23 to 0.696% are used as buffers.
  • the lipid-based compositions of the present invention can be prepared by conventional methods of preparing pharmaceutical suspension compositions.
  • blueberry extract (0.3 to 2 mg/mL) is first added to a lipid mixture containing PEG-12 glyceryl dimistrate (5 to 15%), polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15) (2.5 to 7.5%) and ethyl alcohol (0.7 to 2.1%) at 25 °C ⁇ 1 °C, combining the components by shaking for 10 minutes ⁇ 1 minute.
  • an aqueous base mixture composed of grade 2 purified water (Q.S), anhydrous citric acid (0.04 to 0.16%) and sodium citrate dihydrate (0.23 to 0.69%) at 25 °C ⁇ 1 °C is prepared. , combining the components by shaking for 10 minutes ⁇ 1 minute.
  • the aqueous mixture is added to the lipid mixture at 25 °C ⁇ 1 °C and shaken. for 5 minutes ⁇ 1 minute to thus obtain the final formulation.
  • the resulting lipid-based formulation object of this invention is made up as follows:
  • the formulation makes the penetration and bioavailability of bioactives present in the blueberry extract more efficient in the white tissues of the eyeball due to the use of advanced delivery methods and systems, such as lipid-based systems.
  • Lipid nanoparticles are aqueous colloidal dispersions composed of solid lipids as matrix material with the ability to encapsulate both hydrophilic and lipophilic agents, which ultimately result in thermodynamically stable compounds, with protection for the encapsulated agent, controlled release and biocompatible with the barriers of the globe ocular, easy to produce and with the possibility of being sterilized in an autoclave.
  • Polymeric micelles (10-1 OOnm) comprise amphiphilic block copolymers above the critical micelle concentration with a hydrophobic core and a hydrophilic shell. The micelles prevent or minimize the degradation of the molecules, increase their penetration into the infraocular tissues and also increase their solubility.
  • the resulting formulation can include the following micronutrients:
  • Vitamin E which is a fat-soluble vitamin that has antioxidant effects and works uniquely by breaking the lipid peroxidation chain reaction. This action is crucial to stabilize cell membranes and has been shown to prevent changes to the ocular surface and retina. This vitamin can regenerate other antioxidants such as ascorbic acid or glutathione.
  • Vitamin D since it has shown important effects as an antioxidant in retinal vasculopathies such as diabetic retinopathy.
  • Carotenoids such as Lutein and Zeaxanthin, which are yellow pigments found in vegetables and other plants. Both have the potential to absorb excess light to prevent damage to the neurosensory retina, especially short-wavelength light rays such as violet and blue. Its use is widely used and recognized in ophthalmology. as preventives and/or preservers of retinal health in patients with age-related macular degeneration.
  • liposomes are biocompatible vesicles composed of a phospholipid bilayer with a structural similarity to the cell membrane, which form small spheroids capable of transporting both hydrophilic and lipophilic molecules. They are biocompatible, thermostable and can present a high percentage of encapsulation efficiency of the different compounds.
  • a lipid-based formulation has the potential to improve stability, make penetration of the natural barriers of the eyeball more efficient, and increase the bioavailability of polyphenols in infraocular tissues.
  • EA-LF blueberry extract
  • the pH of EA-LF was analyzed by potentiometer in triplicate at room temperature. Osmolarity was measured by a vapor pressure osmometer in triplicate at 33°C (the ocular surface temperature).
  • Viscosity was also measured in triplicate at 33°C. Viscosity was measured using a thermostatically controlled rheometer when steady state was reached with shear rates increasing from 0 to 1000 s-1.
  • the particle size of the liposomes contained in EA-LF was analyzed by dynamic light scattering and the zeta potential was calculated by measuring the velocity of the particles using a Doppler laser velocimeter at 25°C (Zetasizer Nano ZS, Malvern Instruments). , Malvern, UK).
  • the diameter Z (mean particle diameter) and the polydispersity index (PDI) were calculated from the particle size distribution.
  • the pH of EA-LF was 6.5.
  • the physiological pH range of the tear is between 6.5 and 7.6.
  • the viscosity value of TA-LF was 70 cP (elevated), which could favor their permanence on the ocular surface.
  • the osmolarity was
  • the average particle diameter (z-average) was 167.8 nm, while its PDI was 1 16 and its zeta potential was 0.554, therefore, there is a risk of crystallization of the TA encapsulated in the micelles.
  • the physicochemical characteristics of EA-LF are summarized below.
  • EA-LF samples were kept at 30°C, 40°C and 60°C for three weeks.
  • the pH and the encapsulation efficiency were evaluated on days 0 (baseline) 7, 14 and 21 of thermal incubation.
  • diffusion chambers and New Zealand white rabbit corneas were used to perform in vitro diffusion experiments (BW200S Chemotaxis Chambers, NeuroProbe, Gaithersburg, MD, USA).
  • the central section of the cornea (6 mm in diameter) was located between the upper and lower compartments of the diffusion chambers with the purpose of acting as a diffusion barrier for EA-LF.
  • the upper compartment was filled with 180 ⁇ l of balanced salt solution (BSS) while the lower compartment was filled with 200 ⁇ l of EA-LF.
  • BSS balanced salt solution
  • the diffusion chambers were placed indoors in a humid chamber at 37 °C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention consiste en une formulation à base lipidique à usage topique ophtalmique qui fonctionne comme un système liposomal d'apport des agents bioactifs contenus dans l'extrait de myrtille arbustive dans les tissus blancs du segment postérieur du globe oculaire chez l'être humain. L'invention est utile pour préserver la santé et réduire le risque de développement de processus chroniques dégénératifs dans les tissus intraoculaires, y compris ceux du segment postérieur du globe oculaire, du fait de son activité anti-inflammatoire, anti-angiogénique et antioxydante. La formulation à base lipidique présente le potentiel d'améliorer la stabilité, de rendre plus efficace la pénétration des barrières naturelles du globe oculaire et d'augmenter la biodisponibilité des polyphénols dans les tissus intraoculaires.
PCT/MX2022/050120 2021-12-15 2022-12-05 Formulation à base lipidique à usage topique ophtalmique contenant un extrait de myrtille arbustive WO2023113586A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2021015781A MX2021015781A (es) 2021-12-15 2021-12-15 Formulacion de base lipidica de uso topico oftalmico, que contiene extracto de arandano azul como componente principal para hacer mas eficiente la penetracion y biodisponibilidad de sus bioactivos en tejidos blancos intraoculares en seres humanos.
MXMX/A/2021/015781 2021-12-15

Publications (1)

Publication Number Publication Date
WO2023113586A1 true WO2023113586A1 (fr) 2023-06-22

Family

ID=86773200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2022/050120 WO2023113586A1 (fr) 2021-12-15 2022-12-05 Formulation à base lipidique à usage topique ophtalmique contenant un extrait de myrtille arbustive

Country Status (2)

Country Link
MX (1) MX2021015781A (fr)
WO (1) WO2023113586A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005627A1 (fr) * 2022-06-30 2024-01-04 Centro De Retina Médica Y Quirúrgica, S.C. Formulation à usage topique ophtalmique qui contient de l'extrait de feuille de menthe poivrée à utiliser dans des tissus du globe oculaire chez l'homme

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253745A1 (en) * 2007-11-28 2009-10-08 Sirion Therapeutics, Inc. Modulators of ocular oxidative stress
CN103860625A (zh) * 2013-02-20 2014-06-18 成都尖卡斌科技有限公司 越橘提取物眼用制剂及其制备方法和用途
CN112791113A (zh) * 2020-12-29 2021-05-14 济南瑞隆安生物技术有限公司 一种缓解眼疲劳的蓝莓叶黄素滴眼液及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253745A1 (en) * 2007-11-28 2009-10-08 Sirion Therapeutics, Inc. Modulators of ocular oxidative stress
CN103860625A (zh) * 2013-02-20 2014-06-18 成都尖卡斌科技有限公司 越橘提取物眼用制剂及其制备方法和用途
CN112791113A (zh) * 2020-12-29 2021-05-14 济南瑞隆安生物技术有限公司 一种缓解眼疲劳的蓝莓叶黄素滴眼液及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Aranclean Eye Drops 20 Ml", XP093077137, Retrieved from the Internet <URL:https://supernaturista.com/products/gotas-oftalmicas-aranclean-20-ml-polynaturales> [retrieved on 20230829] *
EMI OOE, TOMOHIRO YAKO, YOSHIKI KUSE, TETSUYA SOGON, SHINSUKE NAKAMURA, MASAMITSU SHIMAZAWA, HIDEAKI HARA: "The protective effects of bilberry extract and its main constituents against blue light-emitting diode (LED) light-induced damage in human corneal epithelial cells", KENKO, EIYO SHOKUHIN KENKYU - JOURNAL OF NUTRITIONAL FOOD, NIHON KENKO, EIYO SHOKUHIN KYOKAI, TOKYO, JP, vol. 17, no. 1, 1 July 2020 (2020-07-01), JP , pages 18 - 33, XP093077136, ISSN: 1345-8388, DOI: 10.20618/jhnfa.17.1_18 *
NAVARRO-PARTIDA JOSÉ, JAUREGUI-GARCÍA GERARDO D., ALTAMIRANO-VALLEJO JUAN C., ACOSTA-GONZÁLEZ RICARDO, GONZÁLEZ-DE LA ROSA ALEJAND: "Novel triamcinolone acetonide-loaded liposomes topical formulation to prevent cystoid macular edema after femtosecond laser-assisted cataract surgery", REVISTA MEXICANA DE OFTALMOLOGÍA, vol. 94, no. 5, 31 August 2020 (2020-08-31), XP093077132, ISSN: 0187-4519, DOI: 10.24875/RMO.M20000126 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005627A1 (fr) * 2022-06-30 2024-01-04 Centro De Retina Médica Y Quirúrgica, S.C. Formulation à usage topique ophtalmique qui contient de l'extrait de feuille de menthe poivrée à utiliser dans des tissus du globe oculaire chez l'homme

Also Published As

Publication number Publication date
MX2021015781A (es) 2023-06-16

Similar Documents

Publication Publication Date Title
US8389014B2 (en) Gel useful for the delivery of ophthalmic drugs
ES2393746T3 (es) Uso de hidroxiestilbenos glucosilados para la prevención y tratamiento de patologías oculares
US20120136048A1 (en) Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
ES2732744T3 (es) Composición para la salud ocular
US20110177171A1 (en) Oxygenated Ophthalmic Compositions and Methods of Use
CN102753163A (zh) 用于预防和/或治疗由紫外线辐射导致的眼病的包含与羟基犬尿氨酸O-β-DL-葡萄糖苷相组合的L-肉碱作为活性成分的组合物
WO2023113586A1 (fr) Formulation à base lipidique à usage topique ophtalmique contenant un extrait de myrtille arbustive
ES2539792T5 (es) Vehículo en forma de una emulsión aceite-en-agua destinado principalmente a una utilización oftálmica o dermocosmética
WO2023113587A1 (fr) Formulation à base lipidique à usage topique ophtalmique, qui contient un extrait de fleur de houblon pour rendre plus efficace la pénétration et la biodisponibilité de ses agents bioactifs dans des tissus blancs intraoculaires chez des êtres humains
CN110090294A (zh) 具有改善的干燥保护和保留的眼用组合物
US8178134B2 (en) Synergistic herbal ophthalmic formulation for lowering intraocular pressure in case of glaucoma
KR20180118951A (ko) 안구 질환 예방 또는 개선용 건강기능식품 조성물
EP3498337A1 (fr) Composition de soulagement, d&#39;amélioration, de prévention et/ou de traitement du syndrome de l&#39; il sec
EP3280395B1 (fr) Compositions ophtalmiques à base d&#39;acides gras polyinsaturés et de triacylglycérols
ES2962253T3 (es) Formulación para la administración oral de extracto del arándano azul como coadyuvante en la conservación de la salud de la película precorneal humana
WO2024005627A1 (fr) Formulation à usage topique ophtalmique qui contient de l&#39;extrait de feuille de menthe poivrée à utiliser dans des tissus du globe oculaire chez l&#39;homme
US12005077B1 (en) Broad-spectrum antimicrobial, biocompatible and preservative-free functionalized fullerenes ophthalmic solution with reactive oxygen species scavenging and advanced targeting, penetration, and hydration
JP2018168168A (ja) ビタミンａ類を含有する水性組成物
US20220184017A1 (en) Compositions for improving eye health and methods of making and using thereof
US20230149337A1 (en) Ophthalmic formulation and its use
Mittal The Role of DHA (Docosahexaenoic acid) in Ophthalmic Microemulsion Formulations: A Comprehensive Review
Truong Development and Evaluation of Quercetin Nanoparticles and Hot Melt Cast Films for Retinal Neuroprotection
BR102020001497A2 (pt) Cloridrato de pilocarpina veiculado em sistema nanocarreador snedds para uso oftalmológico como redutor de pressão intraocular
González-Cela Casamayor Nano y microtecnología aplicada al diseño de nuevas formulaciones para el tratamiento del glaucoma
US20240197649A1 (en) Water-soluble topical ophthalmic preparation containing lutein and production method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22908049

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE